Balance impairment and postural instability are major challenges in older adults and are prominent precursors to falls and loss of independence. The reviewed literature emphasizes a particularly high burden of balance-related disability in people with Type 2 Diabetes Mellitus (T2DM) and those with Alzheimer’s Disease (AD). Historically, clinical frameworks have separated the etiologies: T2DM-associated balance loss has been attributed largely to peripheral complications such as neuropathy, while AD-related instability has been linked to cortical degeneration. The authors argue that this disease-specific compartmentalization overlooks shared, central mechanisms that may drive postural dysfunction across conditions.
This narrative review proposes an integrative model in which three interacting processes—metabolic dysfunction, chronic neuroinflammation, and mitochondrial bioenergetic failure—form a self-reinforcing cycle that underlies balance impairment. According to the review, systemic metabolic abnormalities (including insulin resistance and glucotoxic stress) precipitate central inflammatory pathways. Activation of innate immune signalling, notably the NLRP3 inflammasome, promotes sustained release of proinflammatory cytokines. In turn, this inflammatory environment worsens mitochondrial function and increases oxidative stress, further impairing neuronal and muscular energy metabolism and perpetuating the cycle.
The authors highlight both systemic and cerebral insulin resistance as central metabolic abnormalities linking T2DM and AD to postural instability. Glucotoxicity and impaired insulin signalling are presented as upstream stressors that can induce inflammatory responses and compromise cellular energy handling. The review synthesizes evidence that impaired metabolic control affects not only peripheral tissues but also brain regions responsible for motor control, although specific quantitative measures or trial outcomes are not reported in the source.
A key mechanistic node emphasized is activation of the NLRP3 inflammasome in response to metabolic stressors. This activation leads to increased production of proinflammatory cytokines, creating a chronic neuroinflammatory state. The review links this inflammation to downstream damage in neural circuits and to processes that can accelerate mitochondrial dysfunction. The authors present this inflammatory signalling as a mediator that bridges metabolic disturbance and neuronal bioenergetic failure.
Mitochondrial bioenergetic failure is described as a central consequence of the combined metabolic and inflammatory insults. Increased oxidative stress and compromised mitochondrial function selectively affect high-energy-demand motor circuits, such as the striatum and basal ganglia, which are critical for balance and motor coordination. The review frames mitochondrial dysfunction as both a driver and an amplifier of neuroinflammation and cellular energy failure, contributing to impaired motor control.
The authors link central circuit vulnerability to peripheral manifestations that further degrade postural stability. Mitochondrial and inflammatory processes are implicated in musculoskeletal sarcopenia and peripheral nerve demyelination, both of which reduce strength, sensory input, and postural reflexes. This combination of central motor circuit impairment and peripheral deficits provides a mechanistic explanation for the multifactorial nature of balance impairment in aging individuals with T2DM or AD.
The review discusses potential therapeutic avenues that target nodes within the proposed cycle. Metabolic modulators such as GLP-1 receptor agonists are highlighted for their capacity to modify metabolic dysfunction and possibly reduce inflammation; mitochondrial-targeted antioxidants are proposed to address bioenergetic failure and oxidative stress. The authors present these strategies as promising directions but do not provide new clinical trial data within this narrative review; specific efficacy outcomes or dosing regimens are not reported in the source.
Beyond pharmacologic approaches, the review endorses multimodal rehabilitation strategies that address strength, balance, and functional capacity as complementary interventions. The authors argue that combining metabolic or mitochondrial-targeted therapies with tailored rehabilitation could form the basis of precision interventions to mitigate fall risk and preserve independence in vulnerable aging populations. Details of specific rehabilitation protocols or comparative effectiveness are not provided in the source.
The review advances a unified model that transcends traditional disease-specific explanations for balance impairment by situating metabolic dysfunction, neuroinflammation, and mitochondrial dysfunction at the center of a mutually reinforcing pathological loop. This synthesis highlights shared mechanistic targets for therapeutic development, including metabolic modulation and mitochondria-focused strategies, coupled with multimodal rehabilitation. As a narrative review, the article integrates existing mechanistic and clinical literature but does not report primary experimental or trial results; where granular trial data, effect sizes, or implementation details are needed, those specifics were not reported in the source and require consultation of original studies. Future work should test the proposed framework in translational and clinical studies to establish causal links and define effective, precision-based interventions aimed at reducing falls and functional decline.